Celtaxsys Secures $45M in Capital to Fund Novel Anti-inflammatory Phase 2 Programs in Cystic Fibrosis and Acne
June 8, 2015Celtaxsys completes a $40M Series D financing led by Domain Partners VIII. The proceeds from this financing speaks to the investment community's support for developing innovative anti-inflammatory medicines for patients diagnosed with orphan diseases.
More »
Celator(R) Pharmaceuticals Announces Enrollment is Complete in CPX-351 Phase 2 Study
June 3, 2015Celator completed enrollment in a Phase 2 PK/PD study evaluating the effects of CPX-351 Liposome Injection on cardiac repolarization in acute leukemia patients and they expect to report top-line results from this study by the end of the year.
More »
Celtaxsys Inc. Receives $5M Research Award to Advance Once Daily, Oral Anti-Inflammatory Medicine into Phase 2 CF Patient Lung Function Preservation Trial
June 2, 2015Celtaxsys receives a development award for $5 million from Cystic Fibrosis Foundation Therapeutics, which will help support a Phase 2 clinical trial of the lead candidate, a once daily, oral anti-inflammatory drug to treat cystic fibrosis.
More »